We studied the pharmacokinetics, biodistribution and metabolism of phospho-sulindac (PS), a novel agent efficacious in the treatment of dry eye, formulated in nanoparticles (PS-NPs) following its topical administration to the eye of New Zealand White rabbits. The nanoparticles were spherical with effective diameter = 108.9 ± 41.7 nm, zeta potential = −21.70 ± 3.78 mV, drug loading = 7%, and entrapment efficiency = 46.4%. Of the total PS delivered topically to the eye, > 95% was retained in the anterior segment, predominantly in the cornea (C max = 101.3 μM; T max = 1 h; T 1/2 = 2.6 h; area AUC 0-16h = 164.4 µM·h) and conjunctiva (C max = 89.4 μM; T max = 0.25 h; T 1/2 = 3.1 h; AUC 0-16h = 63.5 µM·h), the tissues most affected by dry eye disease. No PS or its metabolites were detected in the systemic circulation. PS was metabolized to PS sulfide and PS sulfone; all three molecules were hydrolyzed to sulindac, which was converted to sulindac sulfide and sulindac sulfone. A solution formulation of PS provided lower PS levels in ocular tissues but higher levels of PS metabolites, compared to PSNPs. Therefore, NPs represent an effective formulation for the topical ocular administration of PS for anterior segment diseases, such as dry eye disease.
The ocular pharmacokinetics and biodistribution of phospho-sulindac Phospho-sulindac (PS, OXT-328) is a novel agent with anticancer and anti-inflammatory properties. The anticancer properties of PS encompass a variety of tumors, including colon, lung, non-melanoma skin cancer and pancreatic cancer (Cheng et al., 2018; Cheng et al., 2012 Cheng et al., , 2013 Mackenzie et al., 2010; Murray et al., 2014; Zhu et al., 2012) . The anti-inflammatory efficacy of PS has been demonstrated in an animal model of arthritis, in which it was applied topically formulated in a hydrogel and reversed large joint arthritis (Mattheolabakis et al., 2013) . The metabolism, pharmacokinetics (PK) and biodistribution of PS following its oral administration to mice have been reported (Wong et al., 2015; Xie et al., 2012a) . The prominent transformation of PS is its rapid hydrolysis, mainly at its carboxylic ester, by carboxylesterases encountered in the intestinal mucosa and blood, and a series of metabolic transformations dominated by the fate of its main metabolite, sulindac.
Topical drug delivery represents the most accepted route of administration of drugs to the eye, with only 10% of them being administered by intraocular injection or systemic administration (Constantinides et al., 2008) . Despite the easy accessibility of the eye, ophthalmic drug delivery poses major challenges to the pharmaceutical and medicinal sciences, mainly due to the eye's physical barriers to drugs, its enzymes, and the short residence time of drugs on the surface of the eye caused by lacrimation, blinking and nasolacrimal drainage (Agrahari et al., 2016) . In addition, the limited concentration of lipophilic agents in standard ocular formulations for topical delivery contributes to dosage form challenges. Extensive efforts have led to imUsing a novel rabbit model that recapitulates many of the salient features of the human disease, we demonstrated the remarkable efficacy of this compound formulated in nanoparticles (Honkanen et al., 2018) . In particular, in rabbits with DED treated topically for 21 days, PS group restored to normal tear break-up time, osmolarity and lactoferrin levels, and improved the results of the Schirmer test. PS was much more efficacious than cyclosporine or lifitegrast and showed no side effects. Mechanistically, PS suppressed the levels or activity of several pro-inflammatory mediators such as NF-κB, interleukins (IL-1β, IL-6, and IL-8) and matrix metalloproteinases.
Given the therapeutic potential of PS in DED (and perhaps other inflammatory ocular conditions), we studied its PK, biodistribution, and metabolism in the rabbit eye; prior PK and biodistribution studies of PS did not address its topical application to the eye. For these studies, PS was encapsulated into nanoparticles and administered to rabbits topically. The results with PS nanoparticles were compared with those of a solution formulation; solution formulations are commonly used for lipophilic drugs that are structurally similar to PS, e.g., non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac and ketorolac (Lee et al., 2016) . We also determined the PK profile of PS after intravenous administration in order to assess its potential for systemic effects.
Materials and methods

Reagents and animals
PS (OXT-328) was a gift from Medicon Pharmaceuticals, Inc. (Setauket, NY). Its partition coefficient (LogP) between octanol and water is 3.9. Methoxy poly(ethylene glycol)-poly(lactide) (PEG-PLA) was purchased from Akina, Inc. Sodium cholate and dichloromethane were from Sigma-Aldrich (St. Louis, MO) and acetonitrile from BDH Chemicals, VWR (Radnor, PA). Male New Zealand White rabbits, 1800 g-2200 g, were bought from Charles River Laboratories, Kingston NY.
Preparation of PS loaded mPLA-PEG nanoparticles
PS-loaded mPEG-PLA nanoparticles (PS-NPs) were prepared by the emulsion evaporation method (Keum et al., 2011) . Briefly, the oil phase was obtained by dissolving 150 mg of PS and 1 g of mPEG-PLA in 20 mL dichloromethane. The water phase was prepared by dissolving 365 mg of sodium cholate in 60 mL of purified water. Five mL of the oil phase were gently added into 15 mL of the water phase in a 50 mL Eppendorf conical tube. To create an emulsion, we used probe sonication for 2 min at 75% output (Branson 150, Fisher Scientific™, Waltham, MA) . The emulsion was transferred into a 100 mL beaker and stirred overnight at 600 rpm in a chemical hood until the dichloromethane was fully evaporated. The solution was then transferred into ultrafilter tubes (Amicon Ultra-15, Millipore Sigma, Mendota Heights, MN) and centrifuged at 5000×g for 1 h. PBS was added into the resulting concentrated NP solution in the ultrafilter tubes to a volume of 12 mL, and the centrifugation step was repeated once. The concentrated nanoparticles were resuspended into PBS to a final volume of 5 mL, transferred to an Eppendorf tube and spun for 7 s to remove aggregates. The supernatant was harvested as the final product. PS concentration was determined by high-performance liquid chromatography (HPLC) as described below.
2.3. Characterization of PS-NPs 2.3.1. Determination of particle size and zeta potential
The particle size distribution was measured by dynamic light scattering (DLS), using a zeta potential analyzer with the BI-MAS option (ZetaPlus, Brookhaven Instruments Co., Holtsville, NY). All measurements were performed at 25°C in triplicate. The detection angle is 90°f or DLS and 15°for zeta potential.
Examination of particle morphology
The morphology of PS-NPs was examined by transmission electron microscopy (TEM) with negative staining. Briefly, the samples were prepared by wetting a carbon-coated grid with a small drop of diluted nanoparticle solution. Upon drying, they were stained with 1% uranyl acetate and 2% phosphotungstic acid, air-dried at room temperature and viewed with a JEM-1400 Transmission Electron Microscope (JEOL, Peabody, MA).
Encapsulation efficiency (EE) and drug loading capacity (drug-LC)
The total drug encapsulated in nanoparticles was determined by dissolving the nanoparticles into ethanol and conducting HPLC as described in Section 2.7. The total weight of nanoparticles was determined after completely dried in a vacuum oven. The drug loading and encapsulation efficiency were calculated using the following equations: Encapsulation Efficiency, % = (drug encapsulated in nanoparticles/total drug added) × 100%. Drug loading, % = (drug encapsulated in nanoparticles/total weight of nanoparticles) × 100%.
Determination of osmolality and pH
Osmolality of the nanoparticle solution was measured by the MultiSample Osmometer Model 2020 (Advanced Instrument INC, Norwood, MA). Osmolality of 20 μL samples was measured after calibration with reference standards (290 mOsm/kg H 2 O). The pH of the formulations was measured using a calibrated pH meter coupled with a micro pH electrode (Mettler Toledo, Columbus, OH).
Dialysis profile of PS from NPs in vitro
0.1 mL of PS-NP suspension containing 2.7 mg PS was added into a 6 cm dialysis tubing (MWCO 12,000 to 14,000, Carolina, Burlington, NC), its two ends were closed tightly with dialysis clips and dropped into 200 mL 2% Tween 80 in PBS, pH = 7.4 under constant stirring at 350 rpm at 37°C. The beaker was sealed with parafilm membrane (Pechiney, Menasha, WI) to prevent evaporation. Sink condition was maintained during the study. At designated time points, 0.15 mL dialysis buffer was withdrawn. The cumulative percentage release of PS was measured by HPLC. Triplicate experiments were performed. The same experiment was performed for PS solution; the 0.1 mL test sample contained 1 mg PS.
Solution formulation of PS
Polyquaternium-1 (preservative) and Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) were dissolved in purified water, and PS was added to this solution and stirred at 50°C for 30 min. The resultant solution was centrifuged at 13,200 rpm for 10 min and the supernatant was collected. Mannitol and boric acid were added to the supernatant of the previous step. Purified water was added to the final volume after pH adjustment to 6.7 ± 0.2 using NaOH. The final concentrations of this solution were: 3.5% PS, 16% Vitamin E TPGS, 3.18% mannitol, 1.2% boric acid, and 0.005% polyquaternium-1.
PK and biodistribution of PS in rabbit eyes
All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Stony Brook University (protocols 2015-2163-R1 and 714306-3A) . New Zealand White rabbits (♂, 1800 g-2200 g, Charles River Laboratories, Kingston NY) were housed in an environment of 25°C/40% relative humidity and acclimated for 2 weeks. PS formulated either in NPs or in solution (2.0% PS) was administered as 3 eye drops, 25 µL each, 5 min apart. For the PK study, four rabbits (n = 4) were used. Blood was withdrawn at predetermined time-points, i.e., 0.25, 0.5, 1, 2, 4, 8, and 16 h. For the biodistribution study, 2 rabbits (n ≥ 3 eyes) were euthanized at predetermined time-points, i.e., 0.25, 0.5, 1, 2, 4, 8, and 16 h, using Fatal-Plus® solution (Vortech, Dearborn, MI). Eyes and lacrimal glands were collected and kept on ice until sample processing. Eyes were further dissected quickly and tissue samples were frozen in liquid nitrogen and stored until analyzed. Plasma samples were obtained by centrifuging the blood samples, which were deproteinized by immediately mixing with acetonitrile (2 volumes) and centrifuging at 13,200 rpm for 15 min. The supernatant was analyzed by HPLC as described below. Tissue samples were weighed and homogenized using the Bullet Blender Storm 24 (Next Advance, Inc. Averill Park, NY). Following addition of acetonitrile (2 volumes), the mixture was sonicated for 10 min, centrifuged and analyzed by HPLC.
PK of intravenously administered PS
PS prepared in solution (3.5%) as above was given to rabbits through i.v. bolus administration at a dose of 1.8 mg·kg . Four rabbits (n = 4) were used for all time points, i.e., 10 min, 30 min, and 1, 2, 4 and 8 h. Blood samples were obtained at predetermined time points for up to 8 h and processed as above. Levels of PS and its metabolites were determined by HPLC.
HPLC analysis
The HPLC system consisted of a Waters Alliance 2695 Separations Module equipped with a Waters 2998 photo-diode array detector (flow cell length is 1.0 cm) (Waters, Milford, MA) and a BDS Hypersil C18 column (4.6 × 150 mm, particle size 3.0 μm) (Thermo Fisher Scientific, Waltham, MA). Column temperature was maintained at 30°C. The mobile phase consisted of a gradient between 100% of H 2 O with 0.1% formic acid and 100% of Acetonitrile. The mobile phase flow rate is 1.0 mL/min. Wavelength is 328 nm. The injection volume is 40 µL. The entire sample running time is 10 min. Details of this method have been provided elsewhere including typical chromatograms of the compounds studied here (Xie et al., 2012a) .
Data analyses
PK parameters were calculated by Microsoft Excel, PKSolver using non-compartmental analysis. Data are expressed as mean ± SEM (n ≥ 3). SEM values were calculated using Microsoft Excel and applying the standard formula. Statistical analyses were performed by Student's t-test for comparison of the means. P values < 0.05 were considered statistically significant.
Results
Characterization of PS loaded mPLA-PEG nanoparticles
We determined the physicochemical properties of PS-NPs as well as their drug loading and entrapment efficiency. The effective diameter of PS-NPs was 108.9 ± 41.7 nm (diameter ± half width) with a narrow particle size distribution (Fig. 1A) . The zeta potential was −21.70 ± 3.78 mV (mean ± SEM). TEM images (Fig. 1B) demonstrated the formation of nanoparticles with a spherical shape and uniform size distribution. Drug loading and entrapment efficiency were 7.0% and 46.4%, respectively. The osmolality of the nanoparticle formulation was 351 mOsm/kg H 2 O and pH value was 7.10. Fig. 1C . summarizes the in vitro dialysis study using PS-NP. The profile of PS in the receiving solution originating from PS solution and PS-NPs are shown. Results are expressed as the drug accumulation (% total) over 24 h. The amount of PS diffusing out of the dialysis bag reflects to a degree drug release from the nanoparticles; other steps that can be involved are not discerned. 40.6% PS originated from the nanoparticles during the period of observation, while 96.1% of PS originated from the solution formulation.
Ocular PK and biodistribution of PS and its metabolites
We studied the PK properties and biodistribution of PS and its metabolites in the rabbit eye over 16 h after topical administration of PSNPs using HPLC/UV analytical method. All standard curves were made by 5 concentrations, with R value ≥0.9999. The limit of quantitation (LOQ) is 0.05 µM for sulindac, sulindac sulfone, and sulindac sulfide. LOQ of PS is 0.1 µM. Because standard compound of PS sulfone and PS sulfide are not available, the concentrations were calculated according to PS standard curve. Fig. 2 shows the concentration-time curve of intact PS in individual tissues of rabbit eyes, while Table 1 summarizes its PK parameters. Among the various tissues, the highest PS concentration was achieved in the cornea at 1 h (C max = 101.3 μM), with conjunctiva a close second at 0.25 h (C max = 89.4 μM). PS was detectable in cornea and conjunctiva for up to 16 h. In the cornea, PS maintained a relatively high level for a prolonged period of time while in the conjunctiva, its concentration dropped dramatically at 0.5 h. PS biodistribution was essentially restricted to the anterior ocular segment with the area under the curve from 0 to 16 h (AUC 0-16h ) values in the remaining tissues (aqueous humor, iris, ciliary body, and lens) being < 7% of those in cornea and conjunctiva and C max < 5 μM. Surprisingly, a minimal amount of PS was detected in the lacrimal gland. Of note, PS never reached the lens, vitreous body and retina at detectable levels. PS achieved its highest concentration in cornea, aqueous humor and iris at 1 h and in rest of the tissues at 0.25 h, with the elimination half-life varying between 0.7 and 4.0 h.
In vivo, PS is rapidly metabolized into several metabolites, as shown in Fig. 3 (Xie et al., 2012b) . In ocular tissues, we detected a series of known metabolites of PS. Table 2 and Fig. 4 profile the metabolites of PS in cornea and conjunctiva; these two tissues had the greatest concentrations of PS metabolites and are the most important therapeutic targets of PS in DED. In the cornea, PS sulfone, an oxidative product of PS, was the most abundant metabolite; its AUC 0-16h was about 10% of the total uptake of PS. The reductive product of PS, PS sulfide, was present at much lower levels (< 2% of the total AUC 0-16h ). The overall hydrolysis of the ester bond of PS was limited (6% of the total uptake of PS). Interestingly, the conversion of sulindac to sulindac sulfide was limited, representing 5.6% of all hydrolytic products of PS. Sulindac sulfone, which could be derived from hydrolysis of PS sulfone or oxidation of sulindac, showed a much higher AUC (31.8% of all hydrolytic products). Based on metabolite profiles of cornea in Fig. 4 , it is clear that the reduction, oxidation and hydrolysis of PS into PS sulfide, PS sulfone and sulindac is a fast process, followed by its reduction to sulindac sulfide; the oxidation of sulindac to sulindac sulfone is a delayed process (Mattheolabakis et al., 2014) . In contrast to PS sulfone being the dominant metabolite in cornea, in conjunctiva there were more metabolites forming as a result of hydrolysis than oxidation, but their levels were smaller than those in the cornea. No reduction product was detected, such as PS sulfide or sulindac sulfide. The proportion of intact PS in conjunctiva (79.7% of input sulindac) was comparable to that in cornea (81.4%) ( Table 3) .
As depicted in Fig. 5 , in the aqueous humor, the predominant species is PS, followed by significantly lower levels of sulindac, with the rest of the species being either undetectable or ≤0.2 µM. Similar results were obtained in the iris, ciliary body and sclera, except that the level of oxidation products, such as PS sulfone and sulindac sulfone, was higher.
Comparison of PS-NPs to the PS solution formulation
We studied PS and its metabolites in the anterior segment of rabbit eyes at 0.25, 0.5, 1 and 2 h after topical administration of PS in a solution formulation and compared them to that with PS-NP formulation (Table 3 ). There are two major differences between the two formulations in these two pivotal tissues. First, in terms of the concentrations of PS, PS-NPs generated much higher levels compared to PS in solution formulation (1.7 and 2.7 fold higher, respectively). Second, in terms of metabolic degradation of PS in these two tissues, PS was much more protected from hydrolysis when formulated in NPs than in solution. Based on AUC 0-2h following instillation of PS-NPs, as shown in Table 3 , 81.4% of PS remained intact in the cornea, with 7% hydrolytic metabolites and 11.5% oxidized or reduced PS. In contrast, when administered in the solution formulation, PS was extensively hydrolyzed (23.8%) and oxidized (16.8%). In conjunctiva, a similar percentage of PS oxidation products was detected with both PS-NP and solution, but the percentage of hydrolyzed PS was even higher than that in cornea with solution formulation.
Plasma levels of PS and its metabolites after topical and i.v. administration
Following the topical administration of PS-NPs to the eye, PS and its known metabolites were below the limits of detection in peripheral blood at all time points up to 16 h. To further explore the potential biodistribution of PS in the peripheral blood, we administered PS to rabbits by i.v. bolus injection at 1.8 mg·kg
, which equals the amount of PS given topically to both eyes of each rabbit in the previous ocular PK study. As shown in Fig. 6 and Table 4 , the PS concentration at 5 min was 0.4 µM, with its levels becoming undetectable by 30 min. Most of the PS was hydrolyzed to sulindac and its corresponding oxidative metabolite, sulindac sulfone (Valencia et al., 1984) . Sulindac sulfone had the same C max of 1.1 µM at 15 min as sulindac but a longer elimination half-life. No reductive products of PS were detected in the blood.
Discussion
Our results demonstrate that following the topical application of PS to the eye, PS is effectively delivered to targeted tissues in the anterior segment of the eye, the site of the inflammatory reaction that is the pathophysiological hallmark of DED. Our data also make it clear that the nanoparticle formulation of PS is superior to a solution formulation in terms of drug delivery, while both formulations are well tolerated.
Even though one of the smallest organs (7.5 g), the human eye provides the vast majority of the information about our environment and approximately 38% of the neuronal input to the brain (Alward, 2003; Clark and Yorio, 2003) . The need to limit the exposure of such a sensitive and vital organ to the side effects of drugs or drug metabolites is critical. Tissue-targeted drug delivery, an important part of current formulation science, serves that goal. Our NP formulation restricts eye exposure only to the anterior segment of the eye (consisting of the cornea, conjunctiva, aqueous humor, iris, ciliary body, and lens) while the posterior segment is spared (Edward and Kaufman, 2003) . Indeed, in our study, > 95% of PS delivered topically to the eye in NPs was retained in the anterior segment, predominantly in the cornea and conjunctiva, with very limited penetration to the posterior segment of the eye.
Cornea and conjunctiva, clinically the most relevant tissue targets for the control of DED, received the greatest portion of ocular PS. Based on AUC 0-16h values, PS-NPs delivered nearly three times as much PS to the cornea compared to conjunctiva. This could be the result of two complementary processes: higher uptake of PS-NPs by the cornea due in part to the antigen-presenting cells (Baudouin et al., 1997; Edlich et al., 2018) , and diffusion of PS away from the conjunctiva into the blood and lymphatic vessels underlying the fine and leaky conjunctival In all other ocular tissues and the lacrimal gland, the C max is < 5 µM. Table 1 PK parameters of PS in rabbit eyes and lacrimal glands. Tissue PS concentrations after topical administration of PS-NPs to the eye were measured by HPLC and analyzed using PKSolver. Values are mean ± SEM (n ≥ 3). * Cannot be calculated as PS was undetectable. Fig. 3 . Proposed metabolism of PS in ocular tissues. PS can be reduced or oxidized at its sulfur atom, generating PS sulfide and PS sulfone, respectively, or hydrolyzed to sulindac (also generating diethylphosphate and 1,4-butanediol; not shown). Sulindac then undergoes similar transformations at its sulfur atom to sulindac sulfide and sulindac sulfone. No other metabolites were detected in ocular tissues. Table 2 . Samples were obtained 1 h after topical drug application to the eye. a The % refers to the total of PS and its metabolites. Results represent the mean of 3 values.
epithelium. Similar to PS-NPs, the solution formulation delivered PS to essentially all eye tissues of the anterior segment, albeit at significantly lower levels. For example, the cornea level of PS was < 50% of that obtained with PS-NPs at 1 h. The more efficient delivery of PS to ocular tissues by PS-NPs compared to the solution formulation could be explained by the possibility that PS-NPs with particle size ∼110 nm may, in addition to passive diffusion of PS, trigger their uptake by an adsorptive-type endocytosis into the cornea and conjunctiva (Qaddoumi et al., 2004) . This mechanistic possibility and the in vitro release data suggest that PS is taken up by ocular tissues incorporated into nanoparticles, from where it is released and metabolized.
Drug release from biodegradable particles occurs generally through such mechanisms as desorption of drug adsorbed on their surface, diffusion through the particle matrix, bulk degradation or a combined degradation/diffusion process (Sinha and Trehan, 2003) . For PLA NPs, it has been shown that during the early phases release occurs mainly by diffusion through the polymer matrix, whereas later on the drug is released by both diffusion and degradation of the polymer matrix (Budhian et al., 2005) . PS is a hydrophobic compound with very low water solubility (35 µg·mL-1). In our in vitro release study, only about 7.7% of PS was detected in the medium at 2 h. However, the remarkable efficacy of PS-NPs in DED in rabbits (Honkanen et al., 2018) and the detection of metabolites within 2 h after application of PS-NPs indicate that PS is released from NPs in vivo much faster than in vitro (probably a poor so-called "in vitro-in vivo correlation") (Vaishya and Mitra, 2014) , which may be caused by different release condition between in vitro system and in vivo microenvironment, such as pH value and esterase.
The metabolism of PS, when administered through the oral or intraperitoneal route, has been described (Xie et al., 2012a) . In our study of the ocular delivery of PS, no new metabolites specific to the eye nor glucuronidation products were detected. Our findings indicate that in ocular tissues, PS follows three metabolic pathways: a) oxidation/reduction reactions, forming PS sulfide and PS sulfone, respectively; b) hydrolysis reactions, producing sulindac and converting PS sulfide to sulindac sulfide, and PS sulfone to sulindac sulfone; and c) the known metabolism of conventional sulindac, which is converted to sulindac sulfide and sulindac sulfone (Davis and Guenthner, 1985) . Of the metabolites of PS, PS sulfide is likely of similar potency as PS, while PS sulfone and sulindac sulfone are expected to be inactive . Sulindac is a prodrug of sulindac sulfide, which is its active metabolite (Strong et al., 1985) . The solution formulation provides a much higher degree of PS metabolism compared with PS-NPs.
Interestingly, but not surprisingly, no PS or its metabolites are detectable in the systemic circulation after its topical application to the eye. This finding is reinforced by the experiment in which the entire amount of PS applied topically to both eyes was given as an i.v. bolus, , which corresponds to the entire PS administered topically to both eyes of one rabbit in the PK study of PS-NPs shown in Fig. 2 . an extreme situation that would never occur in vivo with topical PS-NP use. Even under that extreme situation, the systemic presence of PS was negligible (< 0.5 μM) and brief. Moreover, the main metabolites of PS, sulindac and sulindac sulfone, were present at low concentrations and no PS or its metabolites were detectable by 4 h. These findings further support the notion that the topical administration of PS in NPs limits this drug to the anterior segment of the eye, a fact that likely contributes to its apparent safety.
Conclusions
Our data establish the advantageous properties of the nanoparticle formulation for the topical delivery of PS for the treatment of diseases of the anterior segment of the eye as compared to a simpler solution formulation. The high levels of PS in the relevant tissues facilitate its therapeutic effect while its limited metabolism and biodistribution should help limit potential untoward effects.
